Diffuse Sclerosing Papillary Thyroid Carcinoma: Clinicopathological Characteristics and Prognostic Implications Compared with Classic and Tall Cell Papillary Thyroid Cancer

被引:2
作者
Scholfield, Daniel W. [1 ]
Fitzgerald, Conall W. [1 ]
Alzumaili, Bayan [2 ]
Eagan, Alana [1 ]
Xu, Bin [2 ]
Martinez, German [2 ]
Tuttle, R. Michael [3 ]
Shaha, Ashok R. [1 ]
Shah, Jatin P. [1 ]
Wong, Richard J. [1 ]
Patel, Snehal G. [1 ]
Ghossein, Ronald A. [2 ]
Ganly, Ian [1 ]
机构
[1] Mem Sloan Kettering Canc Ctr, Dept Surg Head & Neck Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Dept Pathol & Lab Med, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Endocrinol Serv, New York, NY USA
基金
美国国家卫生研究院;
关键词
AGGRESSIVE VARIANTS; SURVIVAL;
D O I
10.1245/s10434-023-13589-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background The clinical behaviour and oncologic outcome of diffuse sclerosing papillary thyroid carcinoma (DS-PTC) is poorly understood. The objectives of this study were to compare the clinicopathological characteristics and oncological outcomes of DS-PTC to classic PTC (cPTC) and tall cell PTC (TC-PTC).Methods After institutional review board approval, 86 DS-PTC, 2,080 cPTC, and 701 TC-PTC patients treated at MSKCC between 1986 and 2021 were identified. Clinicopathological characteristics were compared by using chi-square test. Kaplan-Meier and log rank were used to compare recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS). DS-PTC patients were propensity matched to cPTC and TC-PTC patients for further comparison.Results DS-PTC patients were younger with more advanced disease than cPTC and TC-PTC (p < 0.05). Lymphovascular invasion (LVI), extranodal extension, and positive margins were more common in DS-PTC (p < 0.02). Propensity matching confirmed more aggressive histopathological features in DS-PTC. The median number of metastatic lymph nodes was significantly greater and DS-PTC metastases were RAI avid. DS-PTC 5-year RFS was 50.4% compared with 92.4% in cPTC and 88.4% in TC-PTC (p < 0.001). Multivariate analysis confirmed DS-PTC as an independent prognostic factor of recurrence. Ten-year DSS for DS-PTC was 100% compared with 97.1% in cPTC and 91.1% in TC-PTC. Differentiated high-grade, thyroid carcinoma DS had more advanced T-stage and worse 5-year RFS than DS-PTC.Conclusions DS-PTC presents with more advanced clinicopathological features than cPTC and TC-PTC. Large-volume nodal metastases and LVI are characteristic features. Almost half of patients develop recurrence despite aggressive initial management. Despite this, with successful salvage surgery DSS is excellent.
引用
收藏
页码:4761 / 4770
页数:10
相关论文
共 28 条
  • [1] Amin MB., 2017, AJCC cancer staging manual. Eighth ed
  • [2] Overview of the 2022 WHO Classification of Thyroid Neoplasms
    Baloch, Zubair W.
    Asa, Sylvia L.
    Barletta, Justine A.
    Ghossein, Ronald A.
    Juhlin, C. Christofer
    Jung, Chan Kwon
    LiVolsi, Virginia A.
    Papotti, Mauro G.
    Sobrinho-Simoes, Manuel
    Tallini, Giovanni
    Mete, Ozgur
    [J]. ENDOCRINE PATHOLOGY, 2022, 33 (01) : 27 - 63
  • [3] Special types of thyroid carcinoma
    Baloch, Zubair W.
    LiVolsi, Virginia A.
    [J]. HISTOPATHOLOGY, 2018, 72 (01) : 40 - 52
  • [4] Special variants of differentiated thyroid cancer: Does it alter the extent of surgery versus well-differentiated thyroid cancer?
    Carling, Tobias
    Ocal, Idris T.
    Udelsman, Robert
    [J]. WORLD JOURNAL OF SURGERY, 2007, 31 (05) : 916 - 923
  • [5] Diffuse sclerosing variant of papillary thyroid carcinoma: outcomes of 33 cases
    Cavaco, Daniela
    Martins, Ana Filipa
    Cabrera, Rafael
    Vilar, Helena
    Leite, Valeriano
    [J]. EUROPEAN THYROID JOURNAL, 2022, 11 (01)
  • [6] Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma Is Associated With Aggressive Histopathological Features and a Poor Outcome: Results of a Large Multicentric Study
    Chereau, Nathalie
    Giudicelli, Xavier
    Pattou, Francois
    Lifante, Jean-Christophe
    Triponez, Frederic
    Mirallie, Eric
    Goudet, Pierre
    Brunaud, Laurent
    Tresallet, Christophe
    Tissier, Frederique
    Leenhardt, Laurence
    du Montcel, Sophie Tezenas
    Menegaux, Fabrice
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2016, 101 (12) : 4603 - 4610
  • [7] Papillary Thyroid Cancer-Aggressive Variants and Impact on Management: A Narrative Review
    Coca-Pelaz, Andres
    Shah, Jatin P.
    Hernandez-Prera, Juan C.
    Ghossein, Ronald A.
    Rodrigo, Juan P.
    Hartl, Dana M.
    Olsen, Kerry D.
    Shaha, Ashok R.
    Zafereo, Mark
    Suarez, Carlos
    Nixon, Iain J.
    Randolph, Gregory W.
    Makitie, Antti A.
    Kowalski, Luiz P.
    Vander Poorten, Vincent
    Sanabria, Alvaro
    Guntinas-Lichius, Orlando
    Simo, Ricard
    Zbaren, Peter
    Angelos, Peter
    Khafif, Avi
    Rinaldo, Alessandra
    Ferlito, Alfio
    [J]. ADVANCES IN THERAPY, 2020, 37 (07) : 3112 - 3128
  • [8] Falvo L, 2006, AM SURGEON, V72, P438
  • [9] Clinicopathologic Characteristics and Prognosis of Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma in Japan: An 18-Year Experience at a Single Institution
    Fukushima, Mitsuhiro
    Ito, Yasuhiro
    Hirokawa, Mitsuyoshi
    Akasu, Haruki
    Shimizu, Kazuo
    Miyauchi, Akira
    [J]. WORLD JOURNAL OF SURGERY, 2009, 33 (05) : 958 - 962
  • [10] Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?
    Ganly, Ian
    Nixon, Iain J.
    Wang, Laura Y.
    Palmer, Frank L.
    Migliacci, Jocelyn C.
    Aniss, Ahmad
    Sywak, Mark
    Eskander, Antoine E.
    Freeman, Jeremy L.
    Campbell, Michael J.
    Shen, Wen T.
    Vaisman, Fernanda
    Momesso, Denise
    Corbo, Rossana
    Vaisman, Mario
    Shaha, Ashok
    Tuttle, R. Michael
    Shah, Jatin P.
    Patel, Snehal G.
    [J]. THYROID, 2015, 25 (10) : 1106 - 1114